RAD001 With Weekly Cisplatin and Radiation Therapy in Patients With Locally Advanced Head and Neck Cancer



Status:Not yet recruiting
Conditions:Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:2/4/2013
Start Date:February 2010
Contact:Jochen Lorch, MD
Email:jochen_lorch@dfci.harvard.edu
Phone:617-632-3090

Use our guide to learn which trials are right for you!

A Phase I Trial Using RAD001 With Weekly Cisplatin and Radiation Therapy in Patients With Locally Advanced Head and Neck Cancer


RAD001 is approved by the U.S Food and Drug Administration (FDA) to treat advanced kidney
cancer. This drug has also been used in other research studies to evaluate its
effectiveness in other cancers. Information from these research studies suggests that
RAD001 may help to decrease the growth and development of tumor cells by reducing the blood
supply that tumors need to grow. In this research study, we are trying to determine the
safety of RAD001 when given to people with locally advanced head and neck cancer in
combination with cisplatin and radiation. We are also looking for the highest dose of RAD001
that can be given to people safely.


- Most patients receiving treatment for head and neck cancer will develop difficulty
swallowing food and drinking liquids during the course of therapy. For this reason, it
will be recommended that a PEG (percutaneous endoscopic gastrostomy) tube be placed in
the participants stomach prior to undergoing the study regimen. This is to help
maintain weight and nutritional health.

- Since we are looking for highest dose of the study drug that can be administered safely
without severe or unmanageable side effects, not everyone who participates will receive
the same dose of RAD001 or cisplatin.

- The study regimen will last for seven weeks. During each week of study participation
the following will occur: Radiation will be administered each weekday (5 days per
week). Cisplatin will be given intravenously at the start of each week. RAD001 will be
given to the participant to take at home. Participants will take the study drug once a
day in the morning starting on day 1.

- A history and physical exam will be performed weekly while participant's are receiving
radiation treatment. Blood tests for routine laboratory testing will be performed
weekly.

- Each month for the first two months after participants finish radiation therapy and
stop taking RAD001 and cisplatin, they will have a physical ezam, a neurologic exam,
and blood tests. X-rays, a CT, MRI and/or PET scans will also be performed a the two
month visit. After the first two months, follow-up will continue every 1-2 months for
the first year. Additionally, every 6 months for the first two years, follow-up visits
will include an assessment of speech and swallowing functions along with X-rays, CT,
MRI and/or PET scans.

Inclusion Criteria:

- Patients with stage III/IV, locally advanced, biopsy proven squamous cell cancer of
the head and neck who are planned to undergo chemoradiation as their primary
treatment with curative intent. Patients with oropharynx, hypopharynx, larynx
primaries, nasopharynx as well as those with documented SCC of the cervical lymph
nodes, with unknown primaries, are eligible.

- Patients must have at least evaluable disease and one measurable site of disease
according to RECIST criteria is desirable.

- 18 years of age or older

- Minimum of two weeks since any major surgery

- WHO performance status of 2 or less

- Adequate bone marrow, liver, and renal function as outlined in the protocol

Exclusion Criteria:

- Presence of distant metastatic disease

- Prior chemotherapy

- Prior radiation to the head and neck or adjacent anatomical site

- Chronic treatment with systemic steroids or another immunosuppressive agent

- Patients should not receive immunization with attenuated live vaccines within one
week of study entry or during study period

- Other malignancies within the past 3 years except for adequately treated carcinoma of
the thyroid, cervix or basal or squamous cell carcinomas of the skin

- Patients who have any severe and/or uncontrolled medical conditions or other
conditions that could affect their participation in the study

- Uncontrolled diabetes mellitus

- A known history of HIV seropositivity

- Impairment of gastrointestinal function or gastrointestinal disease that may
significantly alter the absorption of RAD001

- Patients with an active, bleeding diathesis or on oral anti-vitamin K medication

- Women who are pregnant or breastfeeding, or women/men able to conceive and unwilling
to practice an effective method of birth control

- Patients who have received prior treatment with an mTOR inhibitor

- Patients with a known hypersensitivity to RAD001 or other rapamycins or to its
excipients
We found this trial at
1
site
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials